Ellicott City, M.D., June 8, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year relationship with Center Point Clinical Services, a specialty service provider working to improve critical factors in successful clinical trials, including patient satisfaction, retention, and compliance. Center Point will participate as a Global Impact Partner (GIP) and align with 30 other sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.
“Center Point’s commitment to focus on the enhancement of pivotal facets of clinical trials lays the foundation for a strong relationship with SCRS, and therefore clinical research sites globally,” comments Christine Pierre, SCRS President. “SCRS is proud to welcome them to our community, and commends them for their dedication to promoting site sustainability across the clinical research enterprise.”
“Center Point is pleased to join SCRS and to share in its mission to create a unified voice for the clinical research community,” said Gerald Finken, CEO, Center Point. “At Center Point, we strive to truly listen to our patients and to work with sites to deliver the best possible care. Serving as a Global Impact Partner with SCRS and clinical sites will provide us with crucial new perspectives to better understand the needs of our patients.”
As a Global Impact Partner, Center Point will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.